All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Join our
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce
Saturday, November 2, 2024
8:50-9:50 CET
This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
NICE news for carfilzomib
In June 2017, Amgen’s drug carfilzomib was approved by the National Institute for Health and Care Excellence (NICE) for the treatment of patients with Multiple Myeloma (MM), in combination with dexamethasone. Carfilzomib is recommended for the treatment of adult MM patients that have relapsed and had one prior treatment that does not include the proteasome inhibitor (PI) bortezomib. Data from the ENDEAVOR clinical trial was pivotal in this decision, which showed it is superior to bortezomib, in combination with dexamethasone, and can significantly extend progression free survival (PFS) with limited adverse events (AEs). Carfilzomib is administered intravenously and binds irreversibly to the 20S proteasome, inhibiting its activity and leading to cell cycle arrest. This will be welcome news for MM patients in the UK with relapsed disease, who are seeking new and effective options.
Your opinion matters
47 votes - 9 days left ...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox